-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda Pharmaceuticals: The ADC drug TAVATECAN reached two primary endpoints in CLDN 18.2 positive advanced gastric cancer.

Zhitongcaijing·10/23/2026 11:33:24
Listen to the news
Takeda Pharmaceuticals: The ADC drug TAVATECAN reached two primary endpoints in CLDN 18.2 positive advanced gastric cancer.